{"id":971,"date":"2026-04-22T19:29:36","date_gmt":"2026-04-22T19:29:36","guid":{"rendered":"https:\/\/nueva.genolifeadn.com\/?page_id=971"},"modified":"2026-05-05T18:33:33","modified_gmt":"2026-05-05T18:33:33","slug":"biopsia-liquida-oncocell","status":"publish","type":"page","link":"https:\/\/nueva.genolifeadn.com\/en\/biopsia-liquida-oncocell\/","title":{"rendered":"OncoCell Liquid Biopsy"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\tOncoCell Liquid Biopsy\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

OncoCell\u00ae is a liquid biopsy that, from a blood sample, allows the detection of circulating tumor cells (CTCs), considered a key biomarker for early identification of the possible presence or recurrence of cancer.<\/p>

Its use as a follow-up test helps to monitor the patient's health and assess the risk of relapse.<\/p>

Early detection is essential, as many cases are diagnosed in advanced stages due to lack of or confusion of symptoms, which complicates treatment and reduces the chances of recovery.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\tImportance and monitoring with OncoCell\u00ae.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

This study is safe, non-invasive and can be repeated periodically to follow up patients with cancer or suspected cancer. It allows the quantification of specific biomarkers in comparison with healthy individuals, with the presence of CTC being a characteristic indicator of metastasis.<\/p>

Since metastasis causes the majority of cancer deaths, continuous monitoring - recommended every 3 to 4 months - facilitates early detection of relapses and more timely and effective therapeutic decisions.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\tWhat does it consist of and what are its advantages?\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

OncoCell\u00ae is performed by a simple blood draw, followed by a molecular analysis (RT q-PCR) that measures the expression of tumor biomarkers, generating a detailed clinical report.<\/p>

Unlike traditional biopsies or studies such as CT scans, it is less invasive, with no side effects and suitable for frequent monitoring.<\/p>

Based on liquid biopsy technology and supported by genetic profiling with multiple validated biomarkers, this study provides accurate information that supports the physician in the selection of the most appropriate treatment and patient follow-up.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n\t\t\t\t\t
<\/span><\/path><\/svg><\/span>Molecular markers<\/span><\/path><\/svg><\/div>
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Markers for the detection of circulating tumor cells (CTCs).<\/td>\n<\/tr>\n
Ep-CAM (EPCAM)<\/td>\nEpithelial cell adhesion. Molecular marker used for CTC detection.<\/td>\n<\/tr>\n
E-CAD (CDH1)<\/td>\nEpithelial Cadherin (E-CAD), a marker gene used for CTC detection.<\/td>\n<\/tr>\n
CK-7 (KRT7)<\/td>\nCytokeratin 7. Marker for CTC detection.<\/td>\n<\/tr>\n
CK-20 (KRT20)<\/td>\nCytokeratin 20. Marker for CTC detection.<\/td>\n<\/tr>\n
Markers for cell growth monitoring<\/td>\n<\/tr>\n
Ki67 (MKI67)<\/td>\nCell growth factor. Prognostic marker used for breast cancer.<\/td>\n<\/tr>\n
EGFR (EGFR)<\/td>\nEGF receptor. Growth marker present in breast, lung and colorectal cancer, among others.<\/td>\n<\/tr>\n
VEGF (VEGFA)<\/td>\nGrowth factor that stimulates angiogenesis.<\/td>\n<\/tr>\n
Hormonal markers<\/td>\n<\/tr>\n
PR (PR)<\/td>\nProgesterone receptor. Hormone marker.<\/td>\n<\/tr>\n
ER (ESR1)<\/td>\nEstrogen receptor. Hormone marker.<\/td>\n<\/tr>\n
CDX2 (CDX2)<\/td>\nPrognostic score in cancer<\/span> gastric.<\/td>\n<\/tr>\n
ALK (ALK)<\/td>\nTyrosine kinase receptor involved in cell multiplication, present in some types of cancer such as neuroblastoma and non-small cell lung cancer.<\/td>\n<\/tr>\n
Targeted therapy markers<\/td>\n<\/tr>\n
CDKN2B (CDKN2B)<\/td>\nCell growth regulator. Associated with ovarian cancer.<\/td>\n<\/tr>\n
HER-2 (ERBB2)<\/td>\nEGF receptor. Good diagnostic marker for breast, ovarian, lung, prostate, stomach and intestinal cancer.<\/td>\n<\/tr>\n
PDL1 (CD274)<\/td>\nSuppression of the immune system. High tumor expression of PDL1 is associated with increased tumor aggressiveness.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div><\/div>\n\t\t\t\t\t<\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n
\n

OncoCell Liquid Biopsy<\/h2>\n <\/div>\n
\n $<\/span><\/span><\/span><\/span> <\/div>\n
\n